BREAKING NEWS: Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
> Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges
> CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials
> Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024
Read Full Press Release: https://bit.ly/PSTV_PR
More About ReSPECT-LM: https://bit.ly/3lqkKBO
#BrainCancer #ClinicalTrials #BreastCancer #LungCancer #Oncology #Diagnostics
Recent Comments